Merck & Co., Inc. (NYSE:MRK) Announces Earnings Results, Beats Estimates By $0.30 EPS

Merck & Co., Inc. (NYSE:MRK) posted its quarterly earnings results on Tuesday. The company reported $1.74 EPS for the quarter, topping the Zacks’ consensus estimate of $1.44 by $0.30, MarketWatch Earnings reports. The business had revenue of $12.55 billion during the quarter, compared to the consensus estimate of $12.21 billion. Merck & Co., Inc. had a return on equity of 52.94% and a net margin of 22.20%. The company’s revenue for the quarter was up 1.2% compared to the same quarter last year. During the same period last year, the firm earned $1.51 earnings per share. Merck & Co., Inc. updated its FY 2020
Pre-Market guidance to 5.91-6.01 EPS and its FY20 guidance to $5.91-6.01 EPS.

NYSE MRK opened at $76.18 on Thursday. Merck & Co., Inc. has a 12 month low of $65.25 and a 12 month high of $92.64. The company has a debt-to-equity ratio of 0.94, a current ratio of 1.32 and a quick ratio of 1.05. The firm has a market capitalization of $192.68 billion, a PE ratio of 18.58, a P/E/G ratio of 1.98 and a beta of 0.43. The company’s 50 day simple moving average is $81.75 and its 200 day simple moving average is $80.53.

A number of equities analysts recently commented on the company. Mizuho reiterated a “buy” rating on shares of Merck & Co., Inc. in a research note on Tuesday, September 22nd. Royal Bank of Canada reissued a “hold” rating on shares of Merck & Co., Inc. in a report on Tuesday, August 4th. Truist started coverage on shares of Merck & Co., Inc. in a report on Friday, October 23rd. They issued a “buy” rating and a $96.00 target price on the stock. SVB Leerink raised their target price on shares of Merck & Co., Inc. from $95.00 to $100.00 and gave the stock an “outperform” rating in a report on Tuesday, August 25th. Finally, JPMorgan Chase & Co. raised their target price on shares of Merck & Co., Inc. from $98.00 to $105.00 and gave the stock an “overweight” rating in a report on Friday, October 16th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and twelve have given a buy rating to the company. Merck & Co., Inc. presently has a consensus rating of “Buy” and a consensus target price of $95.14.

In other Merck & Co., Inc. news, CFO Robert M. Davis sold 251,273 shares of Merck & Co., Inc. stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $81.03, for a total value of $20,360,651.19. Following the transaction, the chief financial officer now owns 422,329 shares in the company, valued at $34,221,318.87. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Sanat Chattopadhyay sold 10,380 shares of Merck & Co., Inc. stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $83.01, for a total transaction of $861,643.80. The disclosure for this sale can be found here. Insiders have sold 280,529 shares of company stock worth $22,761,633 in the last quarter. Company insiders own 0.28% of the company’s stock.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Recommended Story: Put Option Volume

Earnings History for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.